Drug Trial Radar · NCT02367638
Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Apr 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Planned (sponsor's estimate)
Start
Mar 2015
Primary completion
Jul 2015
Sponsor
- Lead sponsor
- Green Cross CorporationIndustry
- Sponsor type
- Industry
- First posted
- Feb 20, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 20 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether varicella live vaccine is safe and effective in the healthy adults.
Conditions
- Varicella (Chicken Pox)
Interventions
MG1111Biological
Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection
VARIVAXBiological
VARIVAX is administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the solicited adverse events and unsolicited adverse events during 7 days after vaccinationTime frame: 7 days
- To evaluate the unsolicited adverse events during 42 days after vaccinationTime frame: 42 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.